Vitamin D 3 Receptor Activation Rescued Corticostriatal Neural Activity and

Improved Motor Function in –D 2 R Tardive Dyskinesia Mice Model by Bankole, Oluwamolakun O. et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/283080126
Vitamin D 3 Receptor Activation Rescued Corticostriatal Neural Activity and
Improved Motor Function in –D 2 R Tardive Dyskinesia Mice Model
Article  in  Journal of Biomedical Science and Engineering · September 2015
DOI: 10.4236/jbise.2015.88049
CITATION
1
READS
136
10 authors, including:
Some of the authors of this publication are also working on these related projects:
Parkinsonism View project
Working to understand how brain react to nicotine and MDMA use using mice model View project
Oluwamolakun Bankole
University of Verona
7 PUBLICATIONS   28 CITATIONS   
SEE PROFILE
Babafemi J Laoye
Afe Babalola University, Nigeria
7 PUBLICATIONS   28 CITATIONS   
SEE PROFILE
Azeez Ishola
Afe Babalola University
28 PUBLICATIONS   42 CITATIONS   
SEE PROFILE
Esther Oyeleke
College of Medicine University of Lagos
2 PUBLICATIONS   4 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Azeez Ishola on 10 November 2016.
The user has requested enhancement of the downloaded file.
J. Biomedical Science and Engineering, 2015, 8, 520-530 
Published Online August 2015 in SciRes. http://www.scirp.org/journal/jbise 
http://dx.doi.org/10.4236/jbise.2015.88049   
How to cite this paper: Bankole, O.O., et al. (2015) Vitamin D3 Receptor Activation Rescued Corticostriatal Neural Activity 
and Improved Motor Function in –D2R Tardive Dyskinesia Mice Model. J. Biomedical Science and Engineering, 8, 520-530.  
http://dx.doi.org/10.4236/jbise.2015.88049  
 
 
Vitamin D3 Receptor Activation Rescued  
Corticostriatal Neural Activity and  
Improved Motor Function in –D2R  
Tardive Dyskinesia Mice Model 
Oluwamolakun O. Bankole1, Babafemi J. Laoye1, Mujittapha U. Sirjao2, Azeez O. Ishola2, 
Damilola E. Oyeleke2, Wasiu G. Balogun3, Amin Abdulbasit4, Ansa E. Cobham5,  
Ibukun D. Akinrinade6,7, Olalekan M. Ogundele2* 
1Department of Biological Sciences, College of Sciences, Afe Babalola University, Ado-Ekiti, Nigeria 
2Department of Anatomy, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria 
3Department of Anatomy, College of Health Sciences, University of Ilorin, Ilorin, Nigeria 
4Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria 
5Department of Anatomy, College of Medicine, University of Calabar, Calabar, Nigeria 
6Instituto Gulbenkian de Ciencia, Oerias, Portugal 
7Department of Anatomy, Bingham University College of Medicine, Karu, Nigeria 
Email: *ola.ogundele@abuad.edu.ng 
 
Received 23 April 2015; accepted 17 August 2015; published 20 August 2015 
 
Copyright © 2015 by authors and Scientific Research Publishing Inc. 
This work is licensed under the Creative Commons Attribution International License (CC BY). 
http://creativecommons.org/licenses/by/4.0/ 
  
 
 
 
Abstract 
Haloperidol-induced dyskinesia has been linked to a reduction in dopamine activity characterized 
by the inhibition of dopamine receptive sites on D2-receptor (D2R). As a result of D2R inhibition, 
calcium-linked neural activity is affected and seen as a decline in motor-cognitive function after 
prolonged haloperidol use in the treatment of psychotic disorders. In this study, we have eluci-
dated the relationship between haloperidol-induced tardive dyskinesia and the neural activity in 
motor cortex (M1), basal nucleus (CPu), prefrontal cortex (PFC) and hippocampus (CA1). Also, we 
explored the role of Vitamin D3 receptor (VD3R) activation as a therapeutic target in improving 
motor-cognitive functions in dyskinetic mice. Dyskinesia was induced in adult BALB/c mice after 
28 days of haloperidol treatment (10 mg/Kg; intraperitoneal). We established the presence of ab-
normal involuntary movements (AIMs) in the haloperidol treated mice (−D2) through assessment 
of the threshold and amplitude of abnormal involuntary movements (AIMs) for the Limbs (Li) and 
Orolingual (Ol) area (Li and Ol AIMs). As a confirmatory test, the dyskinetic mice (−D2) showed 
high global AIMs score when compared with the VD3RA intervention group (−D2/+VDR) for Li and 
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Ol AIMs. Furthermore, in the behavioral tests, the dyskinetic mice exhibited a decrease in latency 
of fall (LOF; Rotarod-P < 0.05), climbing attempts (Cylinder test; P < 0.05) and latency of Turning 
(Parallel bar test; LOT-P < 0.05) when compared with the control. The reduced motor function in 
dyskinetic mice was associated with a decline in CPu-CA1 burst frequencies and an increase in 
M1-PFC cortical activity. However, after VD3RA intervention (−D2/+VDR), 100 mg/Kg for 7 days, 
CPu-CA1 burst activity was restored leading to a decrease in abnormal movement, and an increase 
in motor function. Ultimately, we deduced that VD3RA activation reduced the threshold of abnor-
mal movement in haloperidol induced dyskinesia. 
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1. Introduction 
Antipsychotics are often employed in the management of depression, schizophrenia and other neurological dis-
orders; however, prolonged use of these drugs often results in tardive dyskinesia (TD) and other associated 
movement disorders [1]. The primary effects of these drugs involve the inhibition of dopaminergic D2 receptor 
in the nigrostriatal system and cortical projections leading to persistent involuntary movements in the face, limbs, 
oral region, trunk and a decline in memory function [2] [3].  
Previous studies have shown that haloperidol-induced motor disorders involve partial inhibition of dopamine 
receptive sites on D2-receptor which prevents the heretomeric combination of D1 and D2 receptors during dopa-
minergic neurotransmission [4]. As a result of the inhibition of D1-D2 combination, calcium transport is im-
paired and this creates a state of D2 receptor sensitivity and calcium-linked oxidative stress [4]-[6].  
An important aspect of drug-induced dyskinesia is its effect on motor-cognitive function due to dopaminergic 
D2 inhibition. Several studies have shown a decline in motor function and cognition after a prolonged use of 
these drugs in treatment of depression and schizophrenia [7] [8]. Going further, the observed behavioral deficits 
were attributed, in part, to loss of dopaminergic neurotransmission in the motor and memory neural systems, 
predominantly due to D2R inhibition and abnormal calcium currents in corticostriatal outputs [3] [5].  
The significance of the D2R stimulation and calcium current supports the wide role of dopamine in various 
brain centers involved in motor and memory functions [5] [9]. Specifically, dopamine interacts with glutamate 
in hippocampal memory formation, striatal motor function, addiction and reward. In addition, glutamate-do- 
pamine cross-talk has been described in glucose metabolism and oxidative stress in these brain centers [10]-[12].  
Our previous experiments have shown that activation of Vitamin D3 receptor (VD3R) reduces calcium toxicity 
through central and peripheral mechanisms, and improves motor-cognitive function in mice after haloperidol 
induced parkinsonism [13]. In the present study, we investigate the link between haloperidol-induced dyskinesia 
and M1, CPu, PFC and CA1 neural activities in vivo. Furthermore, we studied the role of VD3R activation in 
improving motor-cognitive functions through restoration of epoch neural activities in the brain areas of dyski-
netic mice. 
2. Materials 
All chemical reagents were sourced from Sigma-Aldrich, Germany. Haloperidol Injection was procured from 
Kanada Pharmacy, Nigeria and re-suspended in dextrose saline. VD3 was procured form Standard Pharma, Ni-
geria and dissolved in normal saline. Haloperidol and VD3 solutions were prepared weekly as needed and stored 
at 4˚C. 
2.1. Animal Treatment 
BALB/c mice (n = 24) were separated into 4 groups based on body weight distribution. Dyskinesia was induced 
using 10 mg/Kg BW of dopaminergic D2 blocker (Haloperidol i.p. 28 days) in n = 12 animals [13] [14]. Subse-
quently, n = 6 animals were treated with 100 mg/Kg BW (i.p. 7 days) VD3 (−D2/+VDR) while the remaining set 
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of n = 6 animals were untreated (−D2). A separate group of n = 6 animals received VD3 for 28 days (100 mg/Kg 
BW intraperitoneal; +VDR) while the control (n = 6) received normal saline for 28 days (NS; intraperitoneal). 
2.2. Motor Function 
At the end of the treatment phase (Day 28 for Vehicle, −D2, +VDR; Day 35 for –D2/+VDR), the animals were 
examined in various tests for motor function. All animals were familiarized with the behavioral testing tools 
during the treatment phase and were moved to the testing area 72 hours before the commencement of the tests. 
2.3. Motor Function Test for Dyskinesia 
Abnormal Involuntary Movements (AIMs): Involuntary movements were accessed in AIMs (Orolingual 
and Limb AIMs) tests for dyskinesia. The values were recorded as amplitude of movement and basic movement 
using the methods of Cenci and co-workers [15]. Three experienced scientists assessed each animal indepen-
dently using the grading scale of 1 - 4. The average score was adopted in each case for the amplitude and basic 
movement score at 0, 15 and 30 minutes respectively. 
Parallel Bar Test: Motor coordination was accessed on two raised 1m long (1 mm) parallel bars (3 cm apart) 
mounted on the 60 cm high wooden frame. The animal was placed at the 0.5 m mark (center of the raised bars) 
following which we determined the duration taken by the mice to make a 90˚ turn (latency of turning; LOT) 
[16]. 
Rotarod: The test involved three trials of 3 minutes each (T1, T2 and T3) separated by an inter trial time of 90 
minutes. The time spent on the Rotarod in T1, T2 and T3 was determined and averaged to calculate the latency of 
fall (LOF). 
Cylinder Test: Each mouse was placed in a 500 ml transparent beaker (cylinder) and was allowed to explore 
the walls of the cylinder with the forelimbs while standing on the two hind limbs [15]. The number of times an 
animal explored the wall of the cylinder with the forelimb was counted to determine the average score of climb-
ing attempts for each group. 
Bar Test: the magnitude of motor impairment was also measured in the bar test [15]. The forelimbs of the 
animal were placed on a raised wooden bar for 3 minutes. The time taken by the animal to move the limb off the 
raised bar was measured for the treatment and the control groups. 
2.4. Electrophysiology 
Electrophysiological recordings of extracellular calcium hyperpolarization currents were obtained from the basal 
nucleus (CPu), Motor cortex (M1; L4 - L6), Hippocampus (CA1) and the Prefrontal cortex (PFC) using chroni-
cally implanted wire electrodes. Thirty minutes before the implant, animals received 2 mg/Kg i.p. meloxicam 
and were deeply anesthetized using 100 mg/Kg Ketamine and 5 mg/Kg Diazepam (i.p.) to keep the mice immo-
bile but awake for basal motor functions (corneal reflexes and diaphragmatic movement) [17] [18]. Using a ste-
reotaxic frame, the scalp was removed above the bregma to expose the cranium. Periosteal tissue was removed 
using hydrogen peroxide solution and a cotton bud. The M1, CPu, PFC and Hipp were located using a calibrated 
grid to determine the position and depth (electrode length) relative to the bregma [M1 (AP: +3.34 mm ML: +3 
mm DV: +2.5 mm), CPu coordinates (AP: +2.28 mm ML: +3 mm DV: +6 mm), Hipp (AP: −4.4 mm ML: +2 
mm DV: +3 mm), PFC (AP: +2.2 mm ML: +1 mm DV: +2.5 mm)]. A dental drill was used to make holes in the 
cranium following which insulated wire electrodes were inserted to the appropriate depth. The ground electrode 
was placed on the cranium of the contralateral side. Subsequently, the implant was covered by orthodontic resin 
to hold the electrodes in position during the recording procedure. The terminal wires of the electrodes were 
connected to the amplifier through small head-sockets in preparation for immobile awake recordings. The data 
from the amplifier (Spiker Box; Backyard Brains, Michigan, USA) was captured on the Audacity software v4.2 
and analyzed in Sig View v2.1 (Signal Labs, USA) to determine the extracellular summation epoch neural activ-
ity (calcium signals) expressed as Frequency (Hz) per unit time (Figure 1(g) and Figure 2(a)).  
2.5. Statistical Analysis 
Data was presented as mean ± SEM; analyzed using ANOVA and Tukeys Post-Hoc test. Statistical Significance 
was set as P < 0.05*, P < 0.01**, P < 0.001***. 
O. O. Bankole et al. 
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3. Results 
3.1. AIMs Study for Dyskinesia 
The global AIMs score for Limb (Li) and Orolingual (Ol) AIMs were assessed from 0 - 30 minutes after the 
animals were pretreated with 10 mg/Kg Haloperidol (intraperitoneal). Basic and amplitude scores were allotted 
by three independent scientists on a scale of 1 - 4 at 0, 15 and 30 minutes. Subsequently, the basic and amplitude 
scores were converted to the global AIMs score (Basic X Amplitude) for the –D2 group after 28 days of ha-
loperidol treatment to confirm dyskinesia, and –D2/+VDR treatments 7 days after VD3RA intervention (Day 
35). 
Li AIMs: Abnormal involuntary movement was observed in the limbs of the haloperidol treated mice after 28 
days (–D2). The frequency and threshold of such movements increased between 0 - 15 minutes after haloperidol 
treatment and decreased sharply between 15 - 30 minutes. After 7 days of VD3RA intervention (–D2/+VDR), the 
AIMs score decreased significantly when compared with the –D2 at 0 - 15 and 15 - 30 minutes (Figure 3(a)).  
Ol AIMs: Haloperidol treatment (–D2) caused abnormal involuntary movements of the Orolingual area and 
was characterized by uncontrolled chewy mouth movements and tongue protrusion. The threshold (AIMs score) 
was at its peak shortly after haloperidol was given intraperitoneally (0 - 15 minutes) and decreased significantly 
thereafter (15 - 30 minutes). Similar to the observations in Li AIMs, VD3RA intervention also reduced the se-
verity of Ol AIMs when the –D2/+VDR treatment was compared with the –D2 group. Lower AIMs scores were 
recorded in this group throughout the duration of the test (from 0 - 15 and 15 - 30 minutes) (Figure 3(b)). 
Thus, VD3RA treatment after haloperidol induced dyskinesia significantly reduced the threshold of Li and Ol 
AIMs seen as a decline in the AIMs score from 0 - 30 minutes post haloperidol treatment. It is important to 
mention that the mice were also assessed for Axial AIMs (Ax) but showed no significant change in ipsilateral 
and contralateral turns when compared with the control (untreated animals).  
3.2. Motor Function Tests 
After establishing that dyskinesia was induced in the animals, the dyskinesia models (–D2 and –D2/+VDR) were 
compared with the VD3RA treated (+VDR) and untreated control groups (NS) in motor function tests. 
Rotarod: After haloperidol induced dyskinesia (–D2), the LOF decreased significantly on the treadmill when 
compared with the control (P < 0.05). Subsequent VD3RA intervention (–D2/+VDR) caused an increase in the 
LOF (motor function) when compared with the –D2 treatment and the control (P < 0.05). However, VD3RA 
treatment (28 days; +VDR), without prior induced dyskinesia, significantly increased the LOF (motor function); 
when this treatment was compared with the control and the –D2/+VDR (P < 0.01) (Figure 1(a)).  
Cylinder Test: Motor activity was measured as a function of climbing attempts score. Haloperidol induced 
dyskinesia (–D2) caused a decrease in motor activity which was seen as a decline in climbing attempts score 
versus the control (Figure 1(b)). VD3RA intervention in dyskinetic mice (–D2/+VDR) increased the climbing 
attempts to match control scores as no significance was observed between the –D2/+VDR and the control (un-
treated) mice. Similar to our observations in the Rotarod test, VD3RA treatment (+VDR) without prior induced 
dyskinesia significantly increased the climbing attempts (motor function) when compared with the control and 
–D2/+VDR (P < 0.05) (Figure 1(b)). 
Parallel Bar Test: All groups were compared with the untreated control (standard) such that a significant in-
crease or decrease in LOT score was considered a decline in motor function. LOT scores decreased after halope-
ridol induced dyskinesia when the –D2 treatment was compared with the control, thus suggesting a decline in 
motor coordination (P < 0.05). Subsequent VD3RA intervention (–D2/+VDR) significantly increased the LOT 
when compared with the control (P < 0.05) and –D2 (P < 0.001). This outcome suggests a decline in motor coor-
dination when compared with the control as the animals were characterized by freezing of movements on the 
raised bars. VD3RA treatment (+VDR), in non-dyskinetic control mice, caused a decline in LOT when com-
pared with the control (P < 0.05) and was not significant versus –D2 treatment (Figure 1(c)); thus suggesting a 
decline in motor coordination when compared with the control. 
Bar Test: No significant change was observed in the bar test when the treatment groups were compared with 
the control. However, empirical data suggests that –D2, –D2/+VDR and VD3R treatments did induce hyperkine-
sia, thus, causing a reduction in time taken for the mice to remove the limbs from the raised platform (versus the 
control; Figure 1(d)). 
O. O. Bankole et al. 
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3.3. Motor Neural Activity (M1 and CPu) in –D2 Induced Dyskinesia 
Haloperidol induced dyskinesia (–D2) caused a decline in motor function (increase in Ol/Li AIMs), abnormal 
neural activities in the M1 (L4 - L6) and CPu- when the –D2 was compared with the control. Prominent changes 
in the neural spike trains involved an increase in M1 activity (Figure 1(f)) and a reduced threshold of CPu out-
puts when the dyskinetic group (–D2) was compared with the control (Figure 1(e)). After VD3RA intervention 
(–D2/+VDR), an increase in motor activity (decreased threshold of Ol/Li AIMs; Figure 3(a) and Figure 3(b)) 
and CPu neural frequency bursts were observed in the VD3RA intervention group (–D2/+VDR; Figure 1(f)). In 
addition, the threshold of the M1 and CPu activities (RMS) for the intervention group (–D2/+VDR) decreased 
 
      
(a)                                            (b) 
     
(c)                                            (d) 
    
(e)                                            (g) 
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(f) 
Figure 1. ((a)-(d)) Motor function Tests for Dyskinesia and VDRA Treated Haloperidol-Induced dyskinesia Mice Model. (a) 
Rotarod: The latency of fall (LOF) was determined on the treadmill for a test duration of 3 minutes. The dyskinesia group 
(–D2) recorded a reduction in the LOF when compared with the control and the +VDR groups (P < 0.01). However, VD3RA 
intervention in –D2 mice increased the LOF significantly when compared with the –D2 and the control group (P < 0.05). Si-
milarly, VD3RA treatment (only) significantly increased motor function versus the control (P < 0.01); this showed the effect 
of VD3RA in increased motor function in normal and dyskinesia mice model; (b) Cylinder Test: The climbing attempts in the 
cylinder reduced significantly in the –D2 mice when compared with the control (P < 0.05). VD3RA intervention group 
(–D2/+VDR) recorded an increase in climbing attempts when compared with the –D2 treatment and the control. Similar to 
our observations in the Rotarod test, VD3R (only) treatment significantly increased motor function as the +VDR group rec-
orded the highest climbing attempts when compared with the –D2 (P < 0.001) and –D2/+VDR (P < 0.05); (c) Parallel Bar 
Test: The latency of turning (LOT) was reduced in the –D2 treatment; the animals were unstable and constantly moving on 
the bars. VD3RA intervention (–D2/+VDR), however increased the LOT when compared with the –D2 (P < 0.001). The out-
come for the –D2/+VDR can be described as an increase in coordination but a reduction in motor activity when compared 
with the +VDR and –D2 (P < 0.001); (d) Raised Bar Test: No significant change was recorded in this test for the treatment 
groups and the control. ((e)-(g)) Motor Neural Electrophysiological Recording for Dyskinesia Mice Model and VD3RA In-
tervention. ((e)-(f)) Haloperidol treatment induced dyskinesia in Mice after 28 days of intraperitoneal administration. This 
was characterized by a reduction in RMS in the M1 (L4 - L6), loss of burst activity and a reduction in RMS (*) in the CPu 
(Figure 1(f)). VD3RA intervention (–D2/+VDR) reduced the RMS in the M1 and CPu when compared with the control 
(Figure 1(e)) spike pattern (Figure 1(f)). This was also associated with a reduction of Global AIMs score (Ol and Li) and an 
increase in motor coordination when the –D2/+VDR treatment was compared with the –D2 group. VD3RA (only) treatment 
caused an increase in motor activity in control animals when compared with the control (untreated) animals. Neural record-
ings for VD3RA treatment showed a decline in RMS in the M1 (L4 - L6) coupled with a decreased frequency of the spike 
train. However, this group recorded a slight decline in CPu RMS when compared with the control (Figure 1(f)). The de-
creased RMS in VD3RA treatment facilitated a loss of burst action potential in the spike pattern (Figure 1(f)). Thus, it was 
inferred that VD3RA treatment in control animals can cause neural changes seen as hyperactivity in behavioral studies. Sim-
ilar to the observations in –D2, VD3RA also caused a loss of burst pattern in the CPu; in both cases hyperkinesia was ob-
served in the animals; (g) Schematic illustration of chronic unilateral electrode implants in the M1 (L4 - L6) and the CPu. 
 
versus the control and dyskinetic mice (–D2; Figure 1(e) and Figure 1(f)). Furthermore, haloperidol induced 
dyskinesia (–D2) increased M1 but reduced CPu neural outputs and was associated with a decline in motor func-
tion, while VD3RA treatment (VDR+) of control mice decreased M1 activity and was associated with an in-
crease in motor coordination. However, VD3RA intervention after haloperidol induced dyskinesia (–D2/+VDR) 
decreased M1 activity and increased CPu outputs—when compared with –D2—leading to an improvement in 
motor function. From these findings, we deduced loss of CPu burst frequencies was associated with abnormal 
movement in dyskinetic and VD3RA (only) treated mice. By contrast, VD3RA intervention reduced abnormal 
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movements (dyskinesia) by increasing CPu burst frequencies in vivo. From these findings, both M1 and CPu 
neural outputs were affected in dyskinesia and subsequent VD3RA intervention. 
3.4. –D2 induced Dyskinesia Affects Cognition Related Brain Centers 
The effect of haloperidol induced dyskinesia was further investigated on memory-related brain centers (PFC and 
Hipp). Unilateral electrode recordings in immobile awake mice showed a resting state PFC activity and Hippo-
campal CA1 burst in the control. Haloperidol induced dyskinesia increased the PFC frequency in immobile awake 
animals and reduced the CA1 burst activity when compared with the control (Figure 2(c)). This treatment was also 
 
   
(a)                                               (b) 
 
(c) 
Figure 2. Neural Epoch Activity in the PFC and Hippocampus (CA1) of immobile awake dyskinesia and VD3RA interven-
tion mice. (a) Schematic illustration of electrode placement in the PFC and Hippocampus (CA1) regions; ((b)-(c)) The 
dyskinesia group (–D2) recorded an increase in PFC activity but a decrease in CA1 burst when compared with the control 
(Figure 1(c)). VD3RA intervention (–D2/+VDR) facilitated an increase in CA1 burst when compared with the –D2 and the 
control and was associated with an increased CA1 RMS (Figure 2(b)). However, the –D2/+VDR treatment caused a decrease 
in PFC RMS when compared with the control (Figure 2(b)) and was associated with a decrease in spike train frequency. 
Prolonged VD3RA treatment of control animals caused an increase in PFC activity and RMS; also a reduction CA1 burst and 
RMS (Figure 2(b) and Figure 2(c)). 
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characterized by an irregular RMS threshold for PFC and CA1 versus the control (Figure 2(b)). However, 
VD3RA intervention in dyskinetic mice (–D2/+VDR) reduced the PFC neural frequency (reduced RMS thre-
shold) while restoring the CA1 burst pattern (increased RMS threshold). Thus we deduced that VD3RA inter-
vention can significantly restore memory alterations associated with dyskinesia by increasing CA1 burst and re-
ducing PFC activity (opposite for dyskinetic mice). Interestingly, VD3RA treatment of control animals (+VDR), 
however, increased PFC activity and reduced CA1 bursts similar to the effect of –D2. Due to movement impair-
ments, memory function was not assessed in these animals in behavioral tests (Figure 2(b) and Figure 2(c)). 
4. Discussion 
Taken together, the outcome of this study confirms the role of Dopaminergic D2 receptor (D2R) blockade in tar-
dive dyskinesia after prolonged intraperitoneal haloperidol treatment. Similar to the findings in L-DOPA in-
duced dyskinesia model (6-hydroxydopamine; 6-OHDA lesion) [15], haloperidol induced dyskinesia caused 
abnormal involuntary movements in the Orolingual region and Limbs. In this study, we observed no prominent 
change in axial movement when compared with the described symptoms for L-DOPA induced dyskinesia. The 
main abnormal movement observed in the orolingual region and limbs can be described as hyperkinesia (Figure 
3(a) and Figure 3(b)).  
 
 
(a) 
 
(b) 
Figure 3. Abnormal Involuntary Movements (AIMs) Study for Haloperidol induced Dyskinesia and VDRA intervention. (a) 
Limb AIMs (Li): Intraperitoneal Haloperidol treatment for 28 days (–D2) induced prominent limb dyskinesia in the animals 
30 minutes after the treatment. The peak of limb AIMs was observed at 15 minutes and declined rapidly between 20 - 30 
minutes. Interestingly, we observed that VD3RA intervention for 7 days after dyskinesia (–D2/+VDR) significantly reduced 
the severity of the symptoms in these animals. A decline in the global AIMs score was also recorded from 0 minutes to 30 
minutes; (b) OrolingualAIMs (Ol): Haloperidol induced dyskinesia significantly increased the global AIMs score for Oro-
lingual AIMS with prominent constant movement of the mouth and chewy activities. These symptoms were most noticeable 
after haloperidol was administered (0 Minutes) and gradually reduced by 15 - 30 minutes. The –D2/+VDR treatment showed 
very limited signs of uncontrolled Orolingual movements throughout the duration of the experiment and recorded minimal 
global AIMs score when compared with the –D2 treatment 
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Subsequent VD3RA intervention in dyskinetic mice reduced the threshold and amplitude of the Orolingual 
and Limb aims observed over a duration of 30 minutes post haloperidol treatment. The dyskinetic mice (–D2) 
showed a steady increase in abnormal Orolingual movement (Li) from 0 - 15 minutes and this declined rapidly 
between 15 - 30 minutes. Similarly, the global AIMs score for Li was highest within the first 5 minutes after ha-
loperidol treatment and reduced significantly between 15 - 30 minutes. However, VD3RA treatment reduced the 
threshold and amplitude of Li and Ol AIMs when the intervention group (–D2/+VDR) was compared with the 
dyskinetic group (–D2) at 0, 15 and 30 minutes respectively (Figure 3(a) and Figure 3(b)).  
4.1. Haloperidol Induced Dyskinesia 
After confirming the role of haloperidol in –D2 induced dyskinesia, and the effect of VD3RA in ameliorating the 
dyskinesia-linked movement disorders, we examined the general effects of prolonged D2R blockade and VD3RA 
intervention on motor function in these animals using arrays of motor function tests.  
Dyskinetic mice (–D2) showed a decline in motor function in behavioral tests; Rotarod, Cylinder test, parallel 
bar test but exhibited no significant change in the raised bar test when compared with the control. The dyskinetic 
mice recorded a decline in latency of fall (LOF) when compared with the control (P < 0.05; Figure 1(a)). Simi-
larly, these animals scored lower in climbing attempts when assessed in the cylinder test versus control (un-
treated animals) (P < 0.05; Figure 1(b)). Subsequent analysis of motor coordination on raised parallel bars re-
vealed a decline in motor coordination when compared with the control and was seen as a significant decrease in 
latency of turning (LOT) (Figure 1(c); P < 0.05). Surprisingly, these animals showed no significant change in 
motor function when examined for limb removal in a raised bar test and the outcome was rather inconclusive. 
However, this can be attributed to the abnormal movements associated with the limbs (due to tardive dyskinesia) 
rather than a swift removal of limbs as a result of motor coordination (Figures 1(a)-(d)). 
Although the role of VD3RA in Parkinsonism has been studied extensively, its importance in dyskinesia re-
mains poorly explored. Other studies have favored experiments on the effect of Vitamins (Vitamin E) in reduc-
ing the threshold of tardive dyskinesia [19]. The anti-dyskinetic effect of Vitamin E was attributed mostly to its 
antioxidant properties and its role in radical detoxification [19] [20]. Similarly, VD3 deficiency has been linked 
to the cause and progression of various movement disorders [21]; including PD. By virtue to its role in radical 
detoxification, calcium-related signaling and general brain health, VD3 depicts a potential therapeutic target in 
reducing dyskinetic symptoms similar to the effects Vitamin E [22] [23]. In support of this hypothesis, 7 days of 
VD3RA intervention in the dyskinetic mice reduced Ol and Li AIMs, and was associated with an overall im-
provement in motor function when compared with the untreated dyskinetic mice (–D2) (Figure 3(a) and Figure 
3(b), Figure 1(a) and Figure 1(b)). In the Rotarod test, the intervention group (–D2/+VDR) recorded an in-
crease in LOF when compared with the –D2 (untreated dyskinesia) (P < 0.05; Figure 1(a)). Similarly, these an-
imals recorded an increase in climbing attempts score when compared with the untreated mice (–D2) (Figure 
1(b)). These outcomes suggest that VD3RA can reduce dyskinesia significantly, similar to what was described 
for Vitamin E [19]-[21]. 
4.2. Neural Epoch Activity in Dyskinesia 
The abnormal involuntary movement observed after prolonged haloperidol treatment (Figure 3(a) and Figure 
3(b); Figures 1(a)-(d)) were associated with prominent changes in the M1 and CPu neural outputs in deeply se-
dated (immobile awake) mice. Haloperidol induced dyskinesia was characterized by an increase in M1 and CPu 
outputs when compared with the control. This increase in cortical and striatal outputs was attributed to the ob-
served hyperkinesia (AIMs) in this dyskinetic mice; similar to the reports by Lindenbach and Bishop [24]. By 
contrast, VD3RA intervention decreased the M1 cortical output , facilitated CPu burst frequencies and was asso-
ciated with a decrease in global AIMs scores (improved motor function) in the –D2/+VDR. Thus, these observa-
tions, and other reports [25], suggests that a reduction in CPu burst frequency and an increase in M1 cortical 
outputs were associated with the observed motor deficits seen in Dopaminergic receptor inhibition.  
4.3. Corticostriatal Outputs in Dyskinetic Mice 
Haloperidol induced dyskinesia (–D2) decreased CA1 burst and reduced PFC cortical outputs in resting mice 
when compared with the control (Figure 2(c)). Subsequent VD3R intervention (–D2/+VDR) improved motor 
function and was associated with a restoration of hippocampal bursts while reducing the PFC cortical outputs 
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when compared with the untreated dyskinetic mice (–D2; Figure 2(c)). From these observations, we deduced 
that changes in neural activities in the PFC and CA1 were associated with haloperidol induced dyskinesia when 
the M1-CPu was compared with the PFC-CA1 outputs (Figure 1(f) and Figure 2(c)).  
In addition, haloperidol induced dyskinesia increased M1 and PFC (cortical outputs) but decreased the CA1 
and CPu burst frequencies. A similar effect was described by Wang and Goldman-Rakic on the role of D2R in 
control of burst activities through its long term depression (LTD) effects on glutamergic systems; often explored 
in treatment of schizophrenia [26]. However, after VD3RA intervention (–D2/+VDR), restoration of CA1 and 
CPu burst frequencies were observed. This was associated with an increase in motor activity and a decrease in 
the threshold of abnormal movements when the animals were assessed in behavioral tests for motor function. 
These observations suggests that D2R inhibition affects motor and cognitive brain centers sequel to drug induced 
dyskinesia, through disruption of CA1 and corticostriatal projections to the PFC and M1. 
5. Conclusion 
Haloperidol induced dyskinesia was associated with a loss of CPu-CA1 burst pattern and increased M1 neural 
frequencies. VD3RA intervention improved motor function and reduced AIMs score through reversal of M1, 
CPu and CA1 outputs in dyskinetic mice, specifically, restoration of CPu-CA1 burst frequencies.  
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